Investors met Applied Genetic Technologies Corp.’s Nasdaq debut Thursday with tepid interest as the clinical-stage developer of treatments for orphan eye diseases moved to raise $50 million through an initial public offering (IPO) priced at $12 per share, $1 below its intended $13 to $15 range.